MedTrace Logo

Efficiency of Donepezil in Elderly Patients for Prevention of POCD Dysfunction

NCT04423276 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2020-12-29

No results posted yet for this study

Summary

Postoperative cognitive dysfunction (POCD) occurs mainly in aged patients. POCD may increase the mortality and morbidity. However, the mechanism of POCD is not clear yet and no effective therapy method was proved. According to our previous study, the central cholinergic system impaired by the anesthesia and surgery play a very important role in the POCD and donepezil an acetylcholinesterase inhibitor can prevent the POCD after isoflurane anesthesia in aged mice. Donepezil is a commercial medicine used for the Alzheimer Disease, which is tolerable and has minimal adverse events. In present study a multi-center randomized case control study was conducted and we hypothesized that donepezil attenuate the POCD.

Conditions

  • Total Knee Arthroplasty
  • Fracture of Head of Femur Articular Displaced
  • Protrusion of Intervertebral Disc

Interventions

DRUG

Donepezil

Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.

DRUG

Placebo

Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.

Sponsors & Collaborators

  • Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine

    collaborator OTHER

  • Tenth People's Hospital of Tongji Univeristy

    collaborator UNKNOWN

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Diansan Su · Department of Anesthesiology Renji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-14
Primary Completion
2021-12-01
Completion
2022-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04423276 on ClinicalTrials.gov